Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DuPont de Nemours Inc (DD) vs Lam Research Corporation (LRCX) Price & Performance

DuPont de Nemours IncTrade
Lam Research CorporationTrade

Price performance (Past 24H)

Key statistics

DuPont de Nemours Inc vs Lam Research Corporation — how do they compare? DuPont de Nemours Inc trades at $134.21 (market cap $18.12B), while Lam Research Corporation trades at $331.75 (market cap $432.82B). The key difference: Lam Research Corporation is far larger — about 23.9× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays the higher dividend (1.79%). Which is the better fit depends on your goals.

DDLRCX
Market Cap
$18.12B$432.82B
Sector
Basic MaterialsTechnology
52-Week High
$154.59$433.33
52-Week Low
$87.72$94.84
Enterprise Value
$20.58B$431.81B
Dividend Yield
1.79%0.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DuPont de Nemours Inc

DuPont (DD) trades at $132.66, down 1.5% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (35.01%) but negative net income margin (-0.42%) and ROE (-0.16%). Analyst consensus remains bullish with a $227.20 price target (71% upside), though the company faces legal challenges and persistent net cash outflows. Recent developments include water technology upgrades and a 3:1 reverse stock split effective June 2026.

While analyst optimism and valuation discount to price target suggest potential upside, investors face significant risks including ongoing litigation over 'forever chemicals,' weak profitability trends, and concerning cash flow patterns. The stock's current technical weakness near support levels requires careful monitoring of Q2 2026 earnings results due July 2026.

Lam Research Corporation

Lam Research (LRCX) trades at $329.92, down 5.83% amid broader semiconductor sector volatility. The stock shows strong fundamentals with Q1 2026 EPS of $1.47 beating estimates by 8%, marking the third consecutive quarterly beat. Revenue grew 23.8% year-over-year to $18.44B in 2025, while net income margin expanded to 30.94%. Technical indicators show bearish momentum with the stock trading below key resistance at $332, though RSI at 22.63 suggests potential oversold conditions. Recent news highlights AI-driven demand for semiconductor equipment as a key growth catalyst.

LRCX presents a compelling long-term opportunity with 78% analyst buy ratings and $393 consensus price target (19% upside), though elevated P/E of 62.37 warrants caution. Strong cash flow generation ($6.17B operating cash flow) supports dividend payments and strategic investments. Risks include semiconductor cycle volatility and competitive pressures, but AI infrastructure spending provides durable tailwinds for the wafer fabrication equipment leader.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DuPont de Nemours Inc

DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.

Read more on DD

About Lam Research Corporation

Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.

Read more on LRCX